Source comparison
Mechanism Comparison: BPC-157 vs Standard SIBO Treatment
Rifaximin monotherapy Reduces bacterial overgrowth via RNA synthesis inhibition 40–45% within 9 months None. Does not repair epithelial damage None. May temporarily reduce inflammation but does not restore MMC Effective for acute bacterial reduction but fails
This comparison does not assign a generated winner or score.
- Rifaximin monotherapy
- Reduces bacterial overgrowth via RNA synthesis inhibition
- 40–45% within 9 months
- None. Does not repair epithelial damage
- None. May temporarily reduce inflammation but does not restore MMC
- Effective for acute bacterial reduction but fails to address structural causes of recurrence
- Rifaximin + Neomycin
- Combination therapy targeting methanogen species
- 35–40% within 9 months
- None
- Marginally better than monotherapy for methane-dominant SIBO but still neglects gut barrier
- Prokinetic agents (e.g. prucalopride)
- Stimulates 5-HT4 receptors to enhance gut motility
- Variable. Depends on underlying cause
- Moderate. Restores MMC in neurogenic dysfunction
- Addresses motility but not mucosal integrity. Useful adjunct but incomplete monotherapy
- BPC-157 + Rifaximin
- Antibiotic clearance paired with epithelial repair and motility restoration
- 15–20% estimated (limited long-term data)
- High. Accelerates tight junction repair and VEGF-mediated angiogenesis
- Moderate to high. Normalises NO signaling, which indirectly restores MMC
- Most comprehensive approach for structural SIBO. Targets both bacteria and underlying dysfunction
- Here's what stands out: antibiotics alone leave the structural damage untouched. BPC-157 for SIBO fills that gap by repairing the intestinal lining and restoring the motility deficits that allow bacteria to return.